Biophytis SA American Depositary Share (0.01 Euro) Stock Price, News & Analysis

Biophytis (NASDAQ:BPTS) issued its key financial figures for H1 2022 and announced a restatement of its financial statements for 2021. As of June 30, 2022, cash stood at €19.7 million, down from €23.9 million in December 2021. The H1 operating loss rose to €11.9 million due to increased share-based payments. Notably, the COVA clinical study showed a 39% reduction in severe respiratory failure risk in COVID-19 patients. The company plans submissions to regulators by H1 2023 for both SARA and MYODA trials, while a third tranche of €4 million was drawn under the 2021 Atlas contract.

Biophytis (NasdaqCM:BPTS) received a Notification Letter from Nasdaq on October 20, 2022, indicating non-compliance with listing rules due to its ADS closing bid price being below $1.00 for 30 consecutive business days. The Company has a 180-day grace period to regain compliance, expiring on April 18, 2023. While this notification does not immediately affect its listing, Biophytis is actively monitoring its stock price and evaluating options to address the situation. Operations remain unaffected as it continues trading on the Nasdaq Global Select Market.

Biophytis SA (NasdaqCM:BPTS) presented encouraging results for its drug candidate Sarconeos (BIO101) at the 24th Global Investment Conference on September 12, 2022. The CEO, Stanislas Veillet, reported the first results from the phase 2-3 COVA study, demonstrating clinical efficacy in treating COVID-19-related respiratory failure. The COVA study, involving 237 patients, aims to evaluate Sarconeos in older adults with severe COVID-19 symptoms. Biophytis is focused on therapeutics for age-related diseases and has additional studies for Duchenne Muscular Dystrophy.

Biophytis announced on September 8, 2022, that the Paris Court of Appeal ruled in its favor against Negma Group Ltd. This decision reverses a previous penalty of EUR 1.5 million imposed on Biophytis, reducing it to EUR 500,000. The court also mandated Negma to reimburse Biophytis EUR 1 million. This legal victory may positively affect Biophytis's financial standing, enhancing investor confidence. The company continues its clinical development efforts aimed at addressing aging-related diseases, including severe respiratory conditions in COVID-19 patients.

Biophytis announced top-line results from its phase 2-3 COVA clinical study of Sarconeos (BIO101) for treating COVID-19-related respiratory failure. The study involved 233 hospitalized patients, demonstrating a 39% reduction in risk of respiratory failure or early death compared to placebo (15.8% vs 26.0%). While the treatment showed a good safety profile, further analysis is ongoing, with plans to discuss regulatory pathways for market authorization in the US and Europe. The results provide hope for a therapeutic option in a population at risk, emphasizing the need amid ongoing COVID-19 cases.

Biophytis has announced the issuance of 160 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total of €4 million, as part of its existing €32 million convertible bond agreement with Atlas, a New York-based investment fund. This marks the second tranche drawn from the 2021 Atlas contract. The ORNANE contracts do not bear interest and have a 24-month maturity. Upon conversion, the bonds could dilute existing shareholders, reducing a 1% stake to approximately 0.77%. Biophytis is developing therapeutics focused on aging-related diseases, including COVID-19 treatments.

Biophytis (NASDAQ:BPTS) announced an oral presentation on Sarconeos (BIO101) for treating sarcopenia at the 15th International SCWD Congress. Key milestones from the SARA-INT Phase 2 study were discussed, and plans for the SARA Phase 3 study, set to begin by the end of 2022, were outlined. The Phase 3 study aims to enroll 600 to 900 patients aged over 65 with severe sarcopenia and will focus on walking ability and other functional outcomes. The regulatory discussions with EMA and FDA are ongoing to finalize the study design.

Biophytis SA announces the successful adoption of all ordinary and extraordinary resolutions presented during its Combined General Meeting held on June 21, 2022. Over 23% of shareholders participated, approving 26 resolutions, including the consolidated accounts for FY 2021 and the appointment of a new director. The Board of Directors received authority to issue shares to finance company operations. CEO Stanislas Veillet expressed gratitude to shareholders for their support. Biophytis focuses on therapeutics for age-related diseases, with its leading candidate Sarconeos (BIO101) in Phase 2 clinical trials.

Biophytis held its Annual General Meeting on June 3, 2022, but failed to reach the required quorum of 20%, with only 15.45% of shares and 16.19% of voting rights represented. Consequently, no resolutions were voted on, and the meeting was adjourned. Shareholders will be invited to a second AGM at a later date, maintaining the validity of votes submitted previously. Biophytis is a clinical-stage biotechnology company focused on therapeutics for aging-related conditions, including its lead drug candidate Sarconeos (BIO101), targeting severe respiratory failure in COVID-19 patients.